Affy to Expand into Flow Cytometry, Immunology Markets with Planned $330M eBioscience Acquisition | GenomeWeb

This story was originally posted on Dec. 1

By Justin Petrone

Affymetrix last week announced plans to acquire eBioscience, a privately held firm that sells flow cytometry and immunoassay reagents for immunology and oncology research and diagnostics.

The Santa Clara, Calif.-based array vendor said it will spend $330 million in cash and debt to buy eBioscience, with the transaction expected to close before the end of this year.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In PNAS this week: genome sequencing study of Yakutian horses, tardigrade genome, and more.

A guest post at Retraction Watch discusses what funders can do to improve research reproducibility.

Researchers report in Nature this week that farming led to genomic adaptations in humans.

The FDA argues that it needs to evaluate the safety and efficacy of laboratory-developed tests, a proposal that divides Republicans.

Sponsored by
Agilent Technologies

This online seminar will discuss a metagenomic assay to identify viruses and other pathogenic microorganisms in human tumor samples, with the aim of gaining a more comprehensive understanding of the role of the microbiome in cancer development and treatment.